Each week, Medical Device Network journalists select top tweets that summarise the social media buzz in our sector, underpinned by GlobalData’s analytics. These social media signals help us understand brand sentiments and the themes driving conversations on social platforms. This new, thematic coverage is driven by our underlying Disruptor data which tracks all major deals, patents, company filings, hiring patterns and social media buzz across our sectors.
American cardiologist Eric Topol shared research from a US study developing machine learning models for the electrocardiogram (ECG) diagnosis of occlusion myocardial infarction (OMI).
Go deeper with GlobalData
Using 7,313 consecutive patients from multiple clinical sites, the study derived and externally validated an intelligent model that outperformed practicing clinicians and other widely used interpretation systems, substantially boosting both precision and sensitivity.
Topol also tweeted on the latest US SARSCoV2 genomics from the Centers for Disease Control and Prevention (CDC) COVID data tracker which shows continued XBB.1.16 growth advantage vs XBB.1.5 variant.
Latest US #SARSCoV2 genomics shows continued XBB.1.16 growth advantage vs XBB.1.5 varianthttps://t.co/jjl2AnOYb5 with new booster (September) expected to be monovalent XBB.1.5 pic.twitter.com/HGUf9mMCBl
— Eric Topol (@EricTopol) June 23, 2023How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free sampleThank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
An article by the Wall Street Journal also attracted attention. The article highlights how lung cancer causes more deaths than any cancer each year, but only 6% of people eligible get the screening test that can be lifesaving.
